ArticleAngewandte Chemie (International ed. in English)2026
Stereodivergent C-(Hetero)Aryl Glycosylation by Nickel-Catalyzed Redox-Neutral Cross-Coupling of Glycosyl Sulfonyl Hydrazides.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Unprotected C-aryl glycosides are ubiquitous in biologically active compounds and are widely used in chemical biology. The stereochemistry at the anomeric carbon of a C-glycoside often dictates its function. Despite past advances in C-glycosylation, methods that provide selective access to both α and β anomers are scarce due to the challenge of controlling stereoselectivity. Herein, we demonstrate that native sugars, when transformed into glycosyl sulfonyl hydrazide precursors, undergo efficient radical cross-coupling with (hetero)aryl halides under redox-neutral nickel catalysis. The method has broad scope and excellent functional group tolerance, enabling the stereodivergent synthesis of diverse C-(hetero)aryl glycosides in either α or β anomeric forms through ligand control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.